OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Systemic therapy for Asian patients with advanced BRAF V600 ‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
Kenjiro Namikawa, Takamichi Ito, Shusuke Yoshikawa, et al.
Cancer Medicine (2023) Vol. 12, Iss. 17, pp. 17967-17980
Open Access | Times Cited: 12
Kenjiro Namikawa, Takamichi Ito, Shusuke Yoshikawa, et al.
Cancer Medicine (2023) Vol. 12, Iss. 17, pp. 17967-17980
Open Access | Times Cited: 12
Showing 12 citing articles:
Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan
Takuro Noguchi, Shin Ariga, Rika Moku, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Takuro Noguchi, Shin Ariga, Rika Moku, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Prognostic value of the CONUT score with immune checkpoint inhibitors as first‐line therapy for metastatic malignant melanoma
Ken Horisaki, Shusuke Yoshikawa, S. Mori, et al.
The Journal of Dermatology (2025)
Closed Access
Ken Horisaki, Shusuke Yoshikawa, S. Mori, et al.
The Journal of Dermatology (2025)
Closed Access
Genomic profiling and personalized treatment strategies for skin malignancies: findings from the center for cancer genomics and advanced therapeutics database.
Tokimasa Hida
PubMed (2025)
Closed Access
Tokimasa Hida
PubMed (2025)
Closed Access
Deciphering the role of adjuvant therapy in melanoma and its actual benefits
Satoshi Fukushima, Azusa Miyashita, Toshihiro Kimura, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 3, pp. 335-342
Open Access | Times Cited: 2
Satoshi Fukushima, Azusa Miyashita, Toshihiro Kimura, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 3, pp. 335-342
Open Access | Times Cited: 2
Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?
Kenjiro Namikawa, Eiji Nakano, Dai Ogata, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 3, pp. 343-352
Open Access | Times Cited: 2
Kenjiro Namikawa, Eiji Nakano, Dai Ogata, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 3, pp. 343-352
Open Access | Times Cited: 2
Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data
Tokimasa Hida, Junji Kato, Masashi Idogawa, et al.
International Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2
Tokimasa Hida, Junji Kato, Masashi Idogawa, et al.
International Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2
Real‐world efficacy and safety of BRAF ‐targeted therapy for patients with advanced melanoma: A single‐center retrospective study in Japan
Eiji Nakano, Akira Takahashi, Dai Ogata, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 9, pp. 1199-1207
Closed Access | Times Cited: 1
Eiji Nakano, Akira Takahashi, Dai Ogata, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 9, pp. 1199-1207
Closed Access | Times Cited: 1
Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2755-2755
Open Access | Times Cited: 1
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2755-2755
Open Access | Times Cited: 1
A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan
Takamichi Ito, Yumiko Kaku‐Ito, Fumitaka Ohno, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Takamichi Ito, Yumiko Kaku‐Ito, Fumitaka Ohno, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Optimal strategy in managing advanced melanoma
Hiroshi Uchi
The Journal of Dermatology (2023) Vol. 51, Iss. 3, pp. 324-334
Open Access | Times Cited: 2
Hiroshi Uchi
The Journal of Dermatology (2023) Vol. 51, Iss. 3, pp. 324-334
Open Access | Times Cited: 2
Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics
Yujing Shi, Wantong Zhao, Yanbing Ding, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Yujing Shi, Wantong Zhao, Yanbing Ding, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
A retrospective observational study of patients with melanoma prescribed combined BRAF and MEK inhibitors in a real‐world treatment setting in Japan
Kenjiro Namikawa, Kok Yew Ngew, Zuzanna Lukowicz, et al.
Malignancy Spectrum (2024) Vol. 1, Iss. 4, pp. 312-322
Closed Access
Kenjiro Namikawa, Kok Yew Ngew, Zuzanna Lukowicz, et al.
Malignancy Spectrum (2024) Vol. 1, Iss. 4, pp. 312-322
Closed Access
